Apogee stockholders approve AbbVie merger; advisory comp proposal fails

Apogee Therapeutics, Inc.

Merger proposal approved: 46,508,107 for, 3,885 against, 14,261 abstentions, satisfying a closing condition.
Non-binding compensation proposal failed: 19,323,605 for vs 27,123,259 against; not a condition to close.
All seven directors (Henderson, McKenna, Bollinger, Fox, Jones, Kiselak, Shah) to resign effective at merger close.
Special meeting quorum: 46,526,253 shares (74.87% of 62,140,183 outstanding) present.
Apogee to become indirect wholly-owned subsidiary of AbbVie upon merger completion.

Featured in Daily 8-K Digest

Selected #4 for 2026-08-11. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.